5 Most Undervalued Healthcare Stocks to Buy Now

4. MiMedx Group, Inc. (NASDAQ:MDXG)

PE Ratio: 10.00

MiMedx Group, Inc. (NASDAQ:MDXG) is among the most undervalued stocks.

TheFly reported on April 20 that Citizens Financial Group lowered its price target on MDXG from $10 to $7 while maintaining an Outperform rating. The update noted that the company is pursuing significant expense reductions expected to cut annual operating costs by roughly $40 million. However, near-term performance remains under pressure due to slow recovery trends and ongoing reimbursement-related challenges in the wound care market, which continue to weigh on revenue growth. Despite these headwinds, the firm maintained a positive longer-term view, citing MDXG’s strong clinical evidence base, established operational network, and adaptability across evolving care environments.

Earlier on April 16, MiMedx Group, Inc. (NASDAQ:MDXG) announced a restructuring program aimed at lowering operating costs and focusing resources on growth priorities. The initiative is designed to streamline operations and improve efficiency across the business. As part of the changes, the company eliminated the Chief Operating Officer role, previously held by Ricci Whitlow.

The corporation’s Management indicated that further details regarding the restructuring and its financial impact would be shared alongside the first-quarter 2026 earnings discussion during the upcoming conference call later in April, where overall operating performance will also be addressed.

MiMedx Group, Inc. (NASDAQ:MDXG) is a regenerative medicine company specializing in placental biologics. It develops and markets human tissue-based products used for advanced wound care and surgical healing applications.